Ukraine.UroWeb.ru — Український інформаційний портал урологів
(Украинский информационный портал урологов)

Навигация
Главная
О проекте
О нас
Контакты
Журналы
ЛОКЛ
Новости
Конференции и симпозиумы
Профсоюзы
Реформы и предложения
Обращения
Обучение
Библиотека
Лекции
Нормативные документы
Производители
Ссылки
Наши партнеры

Информация для пациентов

Консультации уролога
Форум
Поиск

Ассоциация урологов Украины
Сайт Института урологии Академии медицинских наук Украины
Европейская Ассоциация Урологов
UroWeb.ru - Урологический информационный портал
Explorer.UroWeb.ru — исследователь урологии
Авторизация
Голосования
Удовлетворительная ли у Вас зарпата? Какую Вы бы хотели иметь зарлату?
 
Как Вы оцениваете уровень медицины в Украине (10 баллов максимум)
 


 
Главная
Your mid-month EAU News Update!
21.06.2016
EAU Newsletter Mid-June 2016
Продолжение...
 
Конференція «Сучасні технології в урології»
16.06.2016

Image
ДУ Інститут урології

Національної академії медичних наук України

Шановні колеги!

Пропонуємо ВАМ взяти участь в роботі конференції «Сучасні технології в урології», яка відбудеться в м. Львові 23-24 вересня 2016 року. Наукова сесія відбудеться в конференц-залі готелю «ЛЬВІВ» за адресою:проспект В'ячеслава Чорновола, 7, Львів, Львівська область, 79000

Реєстрація учасників конференції в холі готелю «Львів», з 17.00 до 18.00 23.09.2016. Проживання в готелях м. Львова та регіону. Бронювання самостійне.

Рекомендуємо наступні адреси та готелі - сайти:

Офіційні мови конференції – українська, російська, англійська.

Про згоду участі в конференції прохання повідомити оргкомітет до 30 липня 2016. Тези доповідей просимо надсилати до 30.07.2016. Кількість учасників обмежена !!!.

З повагою доктор медичних наук, професор Шуляк О. В.

 
MEDIA ALERT - ESMO 2016: From disease treatment to patient care
15.06.2016

ESMO 2016 Congress

Bella Center, Copenhagen, Denmark

7-11 October 2016

MEDIA ALERT

ESMO 2016: From disease treatment to patient care

“Learning about the latest advances, discussing the clinical challenges and opportunities for today’s oncologists and learning from each other to achieve a common goal – finding the best outcomes for cancer patients. You can find all this at the ESMO 2016 Congress.”

Fortunato Ciardiello, ESMO President and ESMO 2016 Congress President

 Nearly 2,900 abstracts were submitted for inclusion within the ESMO 2016 Congress, marking a 70% increase over the past six years and confirming the ESMO Congress as the leading oncology event in Europe.

With USA, Italy, Spain, France and Japan being the top five submitters, the ESMO 2016 Congress will be a truly international convention at which to learn about the latest advances in cancer, discuss clinical challenges and share best practices in order to improve patient treatment and care.

More than 19,000 participants from 130 countries worldwide are expected in Copenhagen, from professionals representing various oncology disciplines to healthcare policy makers, and from patient advocates and pharmaceutical companies to international media.

Congress programme highlights:

Продолжение...
 
Endoscopic Diagnosis and Treatment in Urinary Bladder Pathology
15.06.2016

RESEARCH AND MARKETS

Последнее обновление ( 15.06.2016 )
Продолжение...
 
CEM in Vienna: Last Call for Abstracts
15.06.2016

EAU 16th Central European Meeting

Последнее обновление ( 15.06.2016 )
Продолжение...
 
Improve your skills in Endourology and Laparoscopy at ESUT16
09.06.2016
 
Последнее обновление ( 09.06.2016 )
Продолжение...
 
Your EAU News Update - June
09.06.2016
 
 
 
EAU Newsletter June 2016
 
Последнее обновление ( 09.06.2016 )
Продолжение...
 
SIU 2016: SNEAK PEEK!
09.06.2016
Sneak Peek:
SIU 2016 Programme Highlights
SIU 2016 offers a diverse and cutting-edge scientific programme covering a variety of urological topics that address the needs of urologists from various practice and geographical settings. For full programme details, visit our website, or browse some programme highlights below.
Последнее обновление ( 09.06.2016 )
Продолжение...
 
Study Suggests Chemotherapy After Radical Prostatectomy May Benefit Men Who Are At High Risk for Relapse
25.05.2016

San Diego, CA, May 7, 2016 — Not all men with prostate cancer benefit from adjuvant chemotherapy after radical prostatectomy; however, African American men and men with a higher tumor stage may, according to a new U.S. Department of Veterans Affairs (VA) study featured at the 111th Annual Scientific Meeting of the American Urological Association (AUA). The research will be highlighted by study authors during a special press conference. Sam S. Chang, MD, MBA, AUA spokesperson, Patricia and Rodes Hart Chair in Urologic Surgery and Professor of Urologic Surgery at Vanderbilt Medical Center will moderate the session at the San Diego Convention Center in San Diego, CA on May 7, 2016 at 9:15 a.m. PT. 

This year, approximately 200,000 men will be told they have prostate cancer. In the United States alone, it is the leading cause of cancer in Veterans and the second most common cancer in men, affecting one in seven. Odds increase to one in five if the men are African American and one in three if they have a family history. Each year, more than 130,000 men opt for a radical prostatectomy to treat this disease; however, because 20-30 percent of these men will be found to have locally advanced or high-grade disease, they will be at risk for relapse. As such, researchers from VA centers across the U.S. sought to examine the efficacy of early adjuvant chemotherapy on patients who had a radical prostatectomy, but who based on clinical and pathologic parameters, were high risk for relapse.  

Продолжение...
 
Tele-Urology Improves Access and Quality of Care for Patients
25.05.2016

Innovative and Cost-Efficient Technology is Changing How Urologists Care for People Remotely

San Diego, CA, May 6, 2016 – New data highlighting the effectiveness of telemedicine, as well as, innovative screening methods for male infertility using smartphone technology, will be presented during the 111th Annual Scientific Meeting of the American Urological Association (AUA) on Friday, May 6 at 8:30 a.m. The press session will be moderated by Eugene Rhee, MD, MBA, AUA spokesperson and chief of urologic surgery at Kaiser Permanente, San Diego. He is also the recipient of the 2013 AUA Gallagher Health Policy Scholarship.

Telemedicine and the innovative use of technology are considered two of the fastest-growing components within the health care delivery system. Both provide novel and opportune access to hospitals, clinics and health care providers for those who otherwise would have limited to no access.  

Within the urologic community, telemedicine, also referred to as tele-urology, offers several practical uses such as condition diagnosis, general management of care, pre- and postoperative care, second opinions and, possibly, remote surgery. Additionally, for many healthcare organizations that have trouble seeing a high number of patients, tele-urology has the potential to assist in decreasing wait times and increasing quality of care. 

Today’s medicine is also harnessing the power of smartphone and other mobile devices to help better detect conditions, cheaper, better and faster while also accounting for patient comfort and convenience.  

“Ten to fifteen years ago, we never imagined the role technology and mobile devices would have within the urologic community,” said Dr. Rhee. “These platforms are essential to reaching and treating not only today’s patients and with a high quality of care and patient satisfaction, but as well, the next generation of patients and their urologists.”  

Продолжение...
 
Projected Climate Change and Rise in Obesity Levels Expected to Increase Burden of Stone Disease
25.05.2016

Panel discusses emergency department follow-up care, changes in climate and the impact statins have on kidney stones

San Diego, CA, May 6, 2016 — Kidney stones are one of the most common problems of the urinary tract, resulting in more than 300,000 emergency room visits each year. It is estimated that 8.8 percent or roughly one in 11 Americans will have a kidney stone at some point in their life, and that number is expected to increase as a result of climate change, combined with other major risk factors. Three studies highlighting the projected impact of climate, demographics, follow up care and the use of statins on kidney stones will be presented at the 111th Annual Meeting of the American Urological Association (AUA) on Friday, May 6 at 11:00 a.m. at the San Diego Convention Center in San Diego, CA.

The press session will be moderated by Tim Averch, MD, AUA spokesperson, director of the University of Pittsburgh School of Medicine (UPMC) Kidney Stone Center and UPMC professor of urology.

Study Details

Publication Number: PD47-10

Follow-Up Care After ED Visits for Kidney Stones — A Missed Opportunity: Examining MarketScan’s

Commercial Claims and Encounters Database 2003-2006, researchers from University of Michigan in Ann Arbor, MI, sought to investigate whether patients followed the recommended follow-up care after being discharged from the emergency department for kidney stones. Researchers identified adults, ages 18 to 64 with an emergency department visit for kidney stones, then determined which patients had follow-up care within 90 days of the emergency visit. Researchers compared the patients with follow-up care to those without follow-up care over a variety of sociodemographic characteristics. The study found a substantial portion of individuals did not seek follow-up care for kidney stones once they were discharged from the emergency room.

Продолжение...
 
ERUS16: SUBMIT YOUR ABSTRACT BEFORE JUNE 1ST!
25.05.2016
13th Meeting of the EAU Robotic Urology Section
Продолжение...
 
PROJECTED CLIMATE CHANGE AND RISE IN OBESITY LEVELS EXPECTED TO INCREASE BURDEN OF STONE DISEASE
25.05.2016

Projected Climate Change and Rise in Obesity Levels Expected to Increase Burden of Stone Disease

Panel discusses emergency department follow-up care, changes in climate and the impact statins have on kidney stones

San Diego, CA, May 6, 2016 — Kidney stones are one of the most common problems of the urinary tract, resulting in more than 300,000 emergency room visits each year. It is estimated that 8.8 percent or roughly one in 11 Americans will have a kidney stone at some point in their life, and that number is expected to increase as a result of climate change, combined with other major risk factors. Three studies highlighting the projected impact of climate, demographics, follow up care and the use of statins on kidney stones will be presented at the 111th Annual Meeting of the American Urological Association (AUA) on Friday, May 6 at 11:00 a.m. at the San Diego Convention Center in San Diego, CA.

The press session will be moderated by Tim Averch, MD, AUA spokesperson, director of the University of Pittsburgh School of Medicine (UPMC) Kidney Stone Center and UPMC professor of urology.

Study Details

Последнее обновление ( 25.05.2016 )
Продолжение...
 
UROLOGIC SURGICAL PATHOLOGY. EXPERT CONSULT - ONLINE AND PRINT. EDITION NO. 3
25.05.2016
 
RESEARCH AND MARKETS
 
Последнее обновление ( 25.05.2016 )
Продолжение...
 
STREAM OF MLUTS COURSE: TEST YOUR KNOWLEDGE TODAY
25.05.2016
Последнее обновление ( 25.05.2016 )
Продолжение...
 
NTERNATIONAL SURVEY FOR VRE PREVENTION
25.05.2016

Dear ISC Colleague,

We would be grateful if you would participate in this brief International Survey for VRE Infection Prevention with the aim to better understand the practices of VRE control internationally.

It takes just 2-3 minutes to complete, please share with your colleagues both nationally and internationally.

Take Survery HERE

Thank you and Kind regards
 

ISC Secretariat
On behalf of Professor Dale Fisher, ISC OPAT Working Group

 
МІЖРЕГІОНАЛЬНОЇ НАУКОВО-ПРАКТИЧНОЇ КОНФЕРЕНЦІЇ «АКТУАЛЬНІ ПИТАННЯ СУЧАСНОЇ УРОЛОГІЇ, ОНКОУРОЛОГІЇ, СЕКСОПАТОЛОГІЇ ТА АНДРОЛОГІЇ»
04.05.2016

Вельмишановні колеги!

Маємо честь запросити Вас взяти участь у роботі міжрегіональної науково-практичної конференції

 

«АКТУАЛЬНІ ПИТАННЯ СУЧАСНОЇ УРОЛОГІЇ, ОНКОУРОЛОГІЇ,

СЕКСОПАТОЛОГІЇ ТА АНДРОЛОГІЇ»,

яка відбудеться 12-13 жовтня 201року

у м. Яремче

Установи-організатори

  • проведення заходу:
  • ДВНЗ «Івано-Франківський національний медичний університет»,
  • ДОЗ Івано-Франківської ОДА,
  • за підтримки: ДУ «Інститут урології НАМН України»,
  • Український інститут сексології та андрології,
  • Асоціації урологів України, Асоціації онкоурологів України, Асоціації сексологів і андрологів України
Продолжение...
 
HEINE H. HANSEN AWARD GOES TO SURESH SENAN
24.04.2016

PRESS RELEASE

For Immediate Release

Heine H. Hansen Award goes to Suresh Senan

Geneva, Switzerland, 11 April -- The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced the 2016 Heine H. Hansen (HHH) Award recipient as Suresh Senan from Amsterdam. The award will be presented at the European Lung Cancer Conference (ELCC) 2016, held 13 to 16 April in Geneva, Switzerland.

The HHH Award recognises the lifetime contribution of Prof Heine H. Hansen1 to lung cancer research and education globally. Heine Hansen was a president of ESMO, a founder of IASLC and a mentor to many in the field of lung cancer. The HHH Award is presented annually by representatives of both organisations at ELCC, where the awardee will give a keynote lecture.2

The HHH Award acknowledges a lung cancer investigator who has made a special contribution to lung cancer research and education on an international basis. Prof Senan is currently vice-chair of the Department of Radiation Oncology at the VU University Medical Centre in Amsterdam, the Netherlands, where he has been professor of clinical experimental radiotherapy since 2003. He is an ESMO Faculty member for Chest Tumours and has been a member of the IASLC since 2000.

Продолжение...
 
THE JOURNAL OF UROLOGY: APR-2016 (VOLUME 195, ISSUE 4)
24.04.2016
Продолжение...
 
OSIMERTINIB GIVEN AS FIRST-LINE TREATMENT MAY ALTER BIOLOGY OF EGFR MUTATED NSCLC
24.04.2016

PRESS RELEASE

EMBARGOED until 14 April 2016, 02:45 PM hours (CEST)

Osimertinib given as first-line treatment may alter biology of EGFR mutated non-small-cell lung cancer

Presentation at the European Lung Cancer Conference (ELCC)

GENEVA, Switzerland, 14 April 2016 – The third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is effective in the first-line treatment of EGFR mutated non-small-cell lung cancer (NSCLC), according to a late-breaking abstract presented at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1 A second late-breaking abstract confirms the drug’s effectiveness in patients with the T790M mutation.

EGFR inhibition is the standard of care for NSCLC patients with EGFR activating mutations but nearly 50 to 60% develop resistance by developing a T790M mutation. Osimertinib is a potent inhibitor of the original EGFR mutations (exon 19 and exon 21) and the T790M. The study presented today investigated whether the use of osimertinib as first-line therapy for EGFR mutation positive NSCLC would result in favourable efficacy due to delayed T790M mediated resistance.

Продолжение...
 
IMMUNOTHERAPY WITH LIVE BACTERIUM IMPROVES RESPONSE RATE IN MALIGNANT PLEURAL MESOTHELIOMA
24.04.2016

PRESS RELEASE

EMBARGOED until 14 April 2016, 04:45 PM hours (CEST)

Immunotherapy with live bacterium improves response rate in malignant pleural mesothelioma

Presentation at the European Lung Cancer Conference (ELCC)

GENEVA, Switzerland, 14 April 2016 – Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and 59% response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1

“Malignant pleural mesothelioma is a cancer of the lining of the lung and is rare but difficult to treat,” said Prof Thierry Jahan, professor of medicine at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, US. “Standard of care treatment with pemetrexed and platinum compound chemotherapy gets a 30% response rate but a modest impact on survival. So there is a clear unmet need in targeting this specific population.”

Продолжение...
 
ПРОГРАМА НАУКОВО - ПРАКТИЧНОЇ КОНФЕРЕНЦІЇ «АКТУАЛЬНІ ПИТАННЯ СУЧАСНОЇ СЕКСОЛОГІЇ ТА АНДРОЛОГІЇ » 19.05.2016
24.04.2016

Робоча мова: українська, російська, англійська.

ПРОГРАМА

НАУКОВО - ПРАКТИЧНОЇ КОНФЕРЕНЦІЇ

«АКТУАЛЬНІ ПИТАННЯ СУЧАСНОЇ СЕКСОЛОГІЇ ТА АНДРОЛОГІЇ »

19.05.2016

08.00-18.00 РЕЄСТРАЦІЯ УЧАСНИКІВ

08.00-18.00 РОБОТА ВИСТАВОК ФІРМ-СПОНСОРІВ

09.00-10.0АКТОВИЙ ЗАЛ

Продолжение...
 
PATIENTS WITH EGFR EXPRESSING NSCLC BENEFIT MOST FROM NECITUMUMAB ADDED TO CHEMOTHERAPY
24.04.2016

EMBARGOED until 15 April 2016, 09:00 AM hours (CEST)

Patients with EGFR expressing non-small-cell lung cancer benefit most from necitumumab added to chemotherapy

Presentation at the European Lung Cancer Conference (ELCC)

GENEVA, Switzerland, 15 April 2016 – Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1

The randomised phase III SQUIRE trial demonstrated that the addition of necitumumab to gemcitabine and cisplatin chemotherapy improved overall survival in patients with stage IV squamous non-small-cell lung cancer by 1.6 months compared to chemotherapy alone. The current study analysed outcomes in the subgroup of patients with EGFR expressing tumours  compared to those with no EGFRs.

Продолжение...
 
ПРОГРАМА КОНГРЕСУ АСОЦІАЦІЇ УРОЛОГІВ УКРАЇНИ 21 – 23 КВІТНЯ 2016 РОКУ, УКРАЇНА, М.КИЇВ
13.04.2016

Програма Конгресу Асоціації урологів України

21 – 23 квітня 2016 року, Україна, м.Київ

Генеральний спонсор – АСТЕЛЛАС

Спонсори: ООО «УА «ПРО-ФАРМА», Біоноріка, Гранд Медикал Груп АГ

21 квітня

Торгово-промислова палата України (Львівська площа)

Великий зал

8-00 – 9-00 Реєстрація учасників Конгресу. Працює виставка фірм-спонсорів.

9-00 – 9-15 Відкриття Конгресу Асоціації урологів України.

Голова – член-кореспондент НАМН України, професор С.О.Возіанов.

Президія: член-кореспондент НАМН України, професор В.М. Лісовий

Продолжение...
 
NEW! UROwebinar - Update on Bladder Cancer Management
07.04.2016
NEW – UROwebinar by the European School of Urology
Продолжение...
 
6th International Meeting Challenges in Endourology, 29-31 May 2016, Paris, France
07.04.2016
Продолжение...
 
Еще...
<< В начало < Предыдущая 1 2 3 4 5 6 7 Следующая > В конец >>

Всего 253 - 378 из 806
Ukraine.UroWeb.ru - Український інформаційний портал урологів (Украинский информационный портал урологов) © 2018